|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: RC3H1 |
Gene summary for RC3H1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | RC3H1 | Gene ID | 149041 |
| Gene name | ring finger and CCCH-type domains 1 | |
| Gene Alias | FHL6 | |
| Cytomap | 1q25.1 | |
| Gene Type | protein-coding | GO ID | GO:0000209 | UniProtAcc | B9EGU6 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 149041 | RC3H1 | CA_HPV_1 | Human | Cervix | CC | 4.80e-02 | -7.35e-03 | 0.0264 |
| 149041 | RC3H1 | CCI_1 | Human | Cervix | CC | 2.08e-12 | 1.22e+00 | 0.528 |
| 149041 | RC3H1 | CCI_2 | Human | Cervix | CC | 2.41e-09 | 9.53e-01 | 0.5249 |
| 149041 | RC3H1 | CCI_3 | Human | Cervix | CC | 8.67e-12 | 9.03e-01 | 0.516 |
| 149041 | RC3H1 | HTA11_3410_2000001011 | Human | Colorectum | AD | 3.83e-17 | -6.36e-01 | 0.0155 |
| 149041 | RC3H1 | HTA11_99999970781_79442 | Human | Colorectum | MSS | 9.30e-12 | -4.42e-01 | 0.294 |
| 149041 | RC3H1 | HTA11_99999973899_84307 | Human | Colorectum | MSS | 7.83e-04 | -5.65e-01 | 0.2585 |
| 149041 | RC3H1 | HTA11_99999974143_84620 | Human | Colorectum | MSS | 7.46e-16 | -5.56e-01 | 0.3005 |
| 149041 | RC3H1 | F007 | Human | Colorectum | FAP | 6.07e-05 | -2.96e-01 | 0.1176 |
| 149041 | RC3H1 | A001-C-207 | Human | Colorectum | FAP | 1.08e-05 | -3.27e-01 | 0.1278 |
| 149041 | RC3H1 | A015-C-203 | Human | Colorectum | FAP | 1.73e-28 | -3.71e-01 | -0.1294 |
| 149041 | RC3H1 | A015-C-204 | Human | Colorectum | FAP | 2.74e-08 | -3.16e-01 | -0.0228 |
| 149041 | RC3H1 | A014-C-040 | Human | Colorectum | FAP | 1.21e-04 | -3.11e-01 | -0.1184 |
| 149041 | RC3H1 | A002-C-201 | Human | Colorectum | FAP | 1.73e-15 | -3.10e-01 | 0.0324 |
| 149041 | RC3H1 | A002-C-203 | Human | Colorectum | FAP | 4.03e-08 | -2.10e-01 | 0.2786 |
| 149041 | RC3H1 | A001-C-119 | Human | Colorectum | FAP | 7.41e-07 | -1.97e-01 | -0.1557 |
| 149041 | RC3H1 | A001-C-108 | Human | Colorectum | FAP | 3.76e-17 | -3.29e-01 | -0.0272 |
| 149041 | RC3H1 | A002-C-205 | Human | Colorectum | FAP | 8.16e-25 | -3.58e-01 | -0.1236 |
| 149041 | RC3H1 | A015-C-005 | Human | Colorectum | FAP | 5.83e-06 | -2.42e-01 | -0.0336 |
| 149041 | RC3H1 | A015-C-006 | Human | Colorectum | FAP | 2.94e-18 | -5.39e-01 | -0.0994 |
| Page: 1 2 3 4 5 6 7 8 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0046700 | Colorectum | AD | heterocycle catabolic process | 145/3918 | 445/18723 | 4.37e-09 | 2.84e-07 | 145 |
| GO:0006402 | Colorectum | AD | mRNA catabolic process | 87/3918 | 232/18723 | 4.40e-09 | 2.84e-07 | 87 |
| GO:0034655 | Colorectum | AD | nucleobase-containing compound catabolic process | 133/3918 | 407/18723 | 1.56e-08 | 9.12e-07 | 133 |
| GO:0019439 | Colorectum | AD | aromatic compound catabolic process | 146/3918 | 467/18723 | 7.48e-08 | 3.84e-06 | 146 |
| GO:1901361 | Colorectum | AD | organic cyclic compound catabolic process | 153/3918 | 495/18723 | 8.23e-08 | 4.18e-06 | 153 |
| GO:0061013 | Colorectum | AD | regulation of mRNA catabolic process | 64/3918 | 166/18723 | 1.44e-07 | 6.59e-06 | 64 |
| GO:0043487 | Colorectum | AD | regulation of RNA stability | 63/3918 | 170/18723 | 9.17e-07 | 3.12e-05 | 63 |
| GO:0006417 | Colorectum | AD | regulation of translation | 141/3918 | 468/18723 | 1.32e-06 | 4.22e-05 | 141 |
| GO:0043488 | Colorectum | AD | regulation of mRNA stability | 59/3918 | 158/18723 | 1.50e-06 | 4.66e-05 | 59 |
| GO:0000209 | Colorectum | AD | protein polyubiquitination | 78/3918 | 236/18723 | 8.71e-06 | 2.06e-04 | 78 |
| GO:0048872 | Colorectum | AD | homeostasis of number of cells | 87/3918 | 272/18723 | 1.16e-05 | 2.61e-04 | 87 |
| GO:1903313 | Colorectum | AD | positive regulation of mRNA metabolic process | 44/3918 | 118/18723 | 3.20e-05 | 5.87e-04 | 44 |
| GO:0000956 | Colorectum | AD | nuclear-transcribed mRNA catabolic process | 40/3918 | 112/18723 | 2.11e-04 | 2.79e-03 | 40 |
| GO:1900151 | Colorectum | AD | regulation of nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay | 11/3918 | 18/18723 | 2.42e-04 | 3.06e-03 | 11 |
| GO:0061014 | Colorectum | AD | positive regulation of mRNA catabolic process | 32/3918 | 87/18723 | 4.81e-04 | 5.27e-03 | 32 |
| GO:0061157 | Colorectum | AD | mRNA destabilization | 30/3918 | 84/18723 | 1.24e-03 | 1.09e-02 | 30 |
| GO:0033962 | Colorectum | AD | P-body assembly | 11/3918 | 21/18723 | 1.43e-03 | 1.22e-02 | 11 |
| GO:0050779 | Colorectum | AD | RNA destabilization | 30/3918 | 88/18723 | 2.83e-03 | 2.12e-02 | 30 |
| GO:1903706 | Colorectum | AD | regulation of hemopoiesis | 99/3918 | 367/18723 | 3.08e-03 | 2.28e-02 | 99 |
| GO:0001782 | Colorectum | AD | B cell homeostasis | 13/3918 | 31/18723 | 6.53e-03 | 4.06e-02 | 13 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| RC3H1 | SNV | Missense_Mutation | c.2156N>G | p.Tyr719Cys | p.Y719C | Q5TC82 | protein_coding | tolerated(0.14) | benign(0.005) | TCGA-A8-A06T-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | anastrozole | SD | |
| RC3H1 | SNV | Missense_Mutation | c.1324N>A | p.Glu442Lys | p.E442K | Q5TC82 | protein_coding | deleterious(0) | possibly_damaging(0.824) | TCGA-A8-A08B-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR | |
| RC3H1 | SNV | Missense_Mutation | c.2083G>A | p.Glu695Lys | p.E695K | Q5TC82 | protein_coding | deleterious(0.01) | benign(0.021) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| RC3H1 | SNV | Missense_Mutation | c.392G>A | p.Arg131His | p.R131H | Q5TC82 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| RC3H1 | SNV | Missense_Mutation | novel | c.1426N>G | p.Ile476Val | p.I476V | Q5TC82 | protein_coding | tolerated(1) | benign(0.028) | TCGA-AO-A03O-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | doxorubicin | SD |
| RC3H1 | SNV | Missense_Mutation | c.937N>G | p.His313Asp | p.H313D | Q5TC82 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-BH-A0HP-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | doxorubicin | SD | |
| RC3H1 | SNV | Missense_Mutation | c.26N>A | p.Thr9Lys | p.T9K | Q5TC82 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-D8-A1XK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine+cyclophosphamide | SD | |
| RC3H1 | SNV | Missense_Mutation | c.2668T>C | p.Tyr890His | p.Y890H | Q5TC82 | protein_coding | deleterious(0) | possibly_damaging(0.897) | TCGA-D8-A1XQ-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| RC3H1 | SNV | Missense_Mutation | c.1825N>G | p.Gln609Glu | p.Q609E | Q5TC82 | protein_coding | tolerated(0.56) | benign(0.005) | TCGA-E2-A1LA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | arimidex | SD | |
| RC3H1 | SNV | Missense_Mutation | c.835C>G | p.Leu279Val | p.L279V | Q5TC82 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-E9-A1NC-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | CR |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |